|
|
Composite hepatocellular and hemangiosarcomatous tumor: The prognosis is determined by the sarcomatous component |
Giuseppe Orlando a , b , Quirino Lai c , d , Jan Lerut c , ∗ |
a Department of General Surgery, Wake Forest University School of Medicine, Winston-Salem, NC, USA
b Wake Forest Institute for Regenerative Medicine, Wake Forest University School of Medicine, Winston-Salem, NC, USA
c Starzl Unit of Abdominal Transplantation, Pôle de Chirurgie Expérimentale et Transplantation, Institute of Experimental and Clinical Research [IREC], Université catholique de Louvain, Brussels, Belgium
d Department of General Surgery and Organ Transplantation, Sapienza University of Rome, Rome, Italy
∗ Corresponding author.
E-mail address: jan.lerut@uclouvain.be (J. Lerut). |
|
|
Abstract Nowadays, mixed liver tumors are more frequently diagnosed due to better imaging, advanced immunohistochemistry (IHC) staining techniques and better knowledge of hepatic tumorigenesis [1–3]. Such tumors represent a mosaic of components with distinct histogenesis and carcinogenic pathways. As their occurrence in the liver is very rare, their behavior and natural history are difficult to determine, and their management remains empirical. An uncommon case of a composite tumor harboring hepatocellular carcinoma (HCC) and hepatic hemangiosarcoma (HHS) components in a liver transplant (LT) recipient is reported herein.
|
|
|
|
|
|
|
|